# Elutia Inc.: overview ELUT · Nasdaq · CIK 1708527 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/elut.md) · [Financials](/companies/elut/financials.md) · [Filings](/companies/elut/filings.md) · [Insiders](/companies/elut/insiders.md) Latest reported revenue: [$2.4m](/filings/0001104659-26-097292.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001104659-26-097292). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.7](/filings/0001104659-25-110492.md) | [2.8 d](/filings/0001104659-26-027664.md) | [3.0](/filings/0001104659-26-062634.md) | [2.7](/filings/0001104659-26-097292.md) | [3.3](/filings/0001104659-25-110492.md) | [3.3 d](/filings/0001104659-26-027664.md) | [3.1](/filings/0001104659-26-062634.md) | [2.4](/filings/0001104659-26-097292.md) | | Gross margin | % | [48.9%](/filings/0001104659-25-110492.md) | [46.9% d](/filings/0001104659-26-027664.md) | [46.8%](/filings/0001104659-26-062634.md) | [52.9%](/filings/0001104659-26-097292.md) | [55.8%](/filings/0001104659-25-110492.md) | [58.5% d](/filings/0001104659-26-027664.md) | [57.9%](/filings/0001104659-26-062634.md) | [59.6%](/filings/0001104659-26-097292.md) | | Operating margin | % | [(250.5%)](/filings/0001104659-25-110492.md) | [(264.8%) d](/filings/0001104659-26-027664.md) | [(229.7%)](/filings/0001104659-26-062634.md) | [(304.5%)](/filings/0001104659-26-097292.md) | [(156.7%)](/filings/0001104659-25-110492.md) | [(200.6%) d](/filings/0001104659-26-027664.md) | [(203.9%)](/filings/0001104659-26-062634.md) | [(327.9%)](/filings/0001104659-26-097292.md) | | Net margin | % | [35.1%](/filings/0001104659-25-110492.md) | [(321.8%) d](/filings/0001104659-26-027664.md) | [(133.3%)](/filings/0001104659-26-062634.md) | [(349.8%)](/filings/0001104659-26-097292.md) | [(116.4%)](/filings/0001104659-25-110492.md) | [2164.2% d](/filings/0001104659-26-027664.md) | [(239.9%)](/filings/0001104659-26-062634.md) | [(315.0%)](/filings/0001104659-26-097292.md) | | Diluted EPS | $ per share | [(0.33)](/filings/0001104659-25-110492.md) | not reported | [(0.21)](/filings/0001104659-26-062634.md) | [(0.26)](/filings/0001104659-26-097292.md) | [(0.19)](/filings/0001104659-25-110492.md) | not reported | [(0.17)](/filings/0001104659-26-062634.md) | [(0.17)](/filings/0001104659-26-097292.md) | | Free cash flow | $m | [(4.0) d](/filings/0001104659-25-110492.md) | [(12.4) d](/filings/0001104659-26-027664.md) | [(9.2)](/filings/0001104659-26-062634.md) | [(8.3) d](/filings/0001104659-26-097292.md) | [(3.5) d](/filings/0001104659-25-110492.md) | [(25.7) d](/filings/0001104659-26-027664.md) | [(8.3)](/filings/0001104659-26-062634.md) | [(8.6) d](/filings/0001104659-26-097292.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [47.4](/filings/0001558370-23-004475.md) | [23.8](/filings/0001558370-24-002864.md) | [24.7](/filings/0001558370-25-002719.md) | [14.5](/filings/0001104659-26-027664.md) | [12.3](/filings/0001104659-26-027664.md) | | Gross margin | % | [40.1%](/filings/0001558370-23-004475.md) | [48.8%](/filings/0001558370-24-002864.md) | [44.7%](/filings/0001558370-25-002719.md) | [46.4%](/filings/0001104659-26-027664.md) | [53.7%](/filings/0001104659-26-027664.md) | | Operating margin | % | [(48.6%)](/filings/0001558370-23-004475.md) | [(147.5%)](/filings/0001558370-24-002864.md) | [(123.4%)](/filings/0001558370-25-002719.md) | [(212.3%)](/filings/0001104659-26-027664.md) | [(218.9%)](/filings/0001104659-26-027664.md) | | Net margin | % | [(52.4%)](/filings/0001558370-23-004475.md) | [(137.9%)](/filings/0001558370-24-002864.md) | [(152.2%)](/filings/0001558370-25-002719.md) | [(372.9%)](/filings/0001104659-26-027664.md) | [434.2%](/filings/0001104659-26-027664.md) | | Diluted EPS | $ per share | [(2.38)](/filings/0001558370-23-004475.md) | [(2.38)](/filings/0001558370-24-002864.md) | [(2.07)](/filings/0001558370-25-002719.md) | [(1.86)](/filings/0001104659-26-027664.md) | [0.87](/filings/0001104659-26-027664.md) | | Free cash flow | $m | [(15.8)](/filings/0001558370-23-004475.md) | [(22.0)](/filings/0001558370-24-002864.md) | [(22.1)](/filings/0001558370-25-002719.md) | [(23.3)](/filings/0001104659-26-027664.md) | [(46.7)](/filings/0001104659-26-027664.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elut/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.1m | 3,184,947 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.1m | 3,184,947 | | Unchanged | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $2.6m | 2,695,644 | | Reduced −899,606 | | [Knollwood Investment Advisory, LLC](/funds/1999346.md) | 2026-06-30 | $2.5m | 2,556,724 | | Unchanged | | [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $2.1m | 2,192,980 | | Reduced −305,040 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.1m | 1,142,575 | | Added +118,876 | | [PERKINS CAPITAL MANAGEMENT INC](/funds/884300.md) | 2026-06-30 | $379.9k | 694,094 | | Reduced −62,800 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $279.4k | 285,229 | | Reduced −8,167 | | [Corient Private Wealth LP](/funds/1948780.md) | 2026-06-30 | $248.3k | 253,500 | | Added +4,468 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $197.7k | 201,816 | | Added +119,100 | ## Recent filings [All 369 filings](/companies/elut/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-21 | 17:00 ET | [8-K](/filings/0001104659-26-099731.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-099731 | | 2026-08-14 | 16:45 ET | [10-Q](/filings/0001104659-26-097292.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097292 | | 2026-08-13 | 16:15 ET | [8-K](/filings/0001104659-26-095934.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-095934 | | 2026-08-07 | 16:15 ET | [8-K](/filings/0001104659-26-092718.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001104659-26-092718 | | 2026-07-20 | 16:06 ET | [8-K](/filings/0001104659-26-085061.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-085061 | | 2026-06-16 | 17:00 ET | [8-K](/filings/0001104659-26-074660.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-074660 | | 2026-05-15 | 16:31 ET | [10-Q](/filings/0001104659-26-062634.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062634 | | 2026-05-14 | 16:06 ET | [8-K](/filings/0001104659-26-061150.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-061150 | | 2026-04-22 | 17:00 ET | [DEF 14A](/filings/0001104659-26-046897.md) | Proxy statement, period 2026-06-11 | 0001104659-26-046897 | | 2026-03-13 | 16:11 ET | [10-K](/filings/0001104659-26-027664.md) | Annual report, period 2025-12-31 | 0001104659-26-027664 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-027664.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/172327c8-1eac-4c63-a248-553f41ad48f8) ## About the filer - CIK: 1708527 - Tickers: ELUT - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.